Novo Nordisk A/S (TSX:NOVO)

Market Cap	292.55B -44.9%
Revenue (ttm)	66.62B +6.4%
Net Income	22.08B +1.4%
EPS	4.96 +1.8%
Shares Out	n/a
PE Ratio	13.25
Forward PE	14.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,222
Average Volume	19,216
Open	19.84
Previous Close	20.95
Day's Range	19.56 - 20.21
52-Week Range	18.44 - 27.58
Beta	n/a
RSI	32.28
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 78,554
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: NOVO

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK